Absci (ABSI) Receivables - Net (2023 - 2025)

Absci's (ABSI) quarterly Receivables - Net came in at $1.0 million in Q3 2025, up 42.86% quarter-over-quarter from $700000.0 in Q2 2025.

Absci (ABSI) Receivables - Net (2023 - 2025) Analysis & Trends

Absci has disclosed Receivables - Net across 2 years of filings, most recently posting $1.0 million for Q3 2025.

Receivables - Net for Q3 2025 came in at $1.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $1.0 million (changed N/A YoY), and the FY2023 annual result was $2.2 million, changed N/A from the prior year.
Receivables - Net came in at $1.0 million for Q3 2025 at Absci, up from $700000.0 in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $2.2 million in Q4 2023 to a low of $700000.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Absci	1.13 Bn	1.01 Bn	-

Download Data